News Photo

Bold Therapeutics BOLD-100 Early mCRC Data to be Showcased at 2022 Metals in Medicine Gordon Research Conference

Bold Therapeutics is excited to share compelling early efficacy data on BOLD-100 at the 2022 Metals in Medicine Gordon Research Conference.

Read more
Post Photo

05-10-2022

Bold Therapeutics to Present at Bio Korea 2022 as part of the Canadian Trade Delegation

Bold Therapeutics is pleased to have been invited to present at Bio Korea 2022 as part of the Canadian trade delegation.


Post Photo

04-06-2022

BOLD-100s Broad Potential Featured at the AACR Annual Meeting 2022

Bold Therapeutics announced that it will present research supporting the use of BOLD-100 at the AACR Annual Meeting 2022 on April 8-13, 2022 in New Orleans.


Post Photo

04-04-2022

Bold Therapeutics Selected as 2nd Place Winner at 2022 Innovator Pitch Challenge

Bold Therapeutics is excited to announce second place in the Innovator’s Pitch Challenge at the Digital Redefining Early-Stage Investments Conference.


Post Photo

03-10-2022

Bold Therapeutics Successfully Completes Phase 1b Trial and Advances into Global Phase 2 Trial of BOLD-100 in the Treatment of Advanced GI Cancers

Bold Therapeutics successfully completed Phase 1b of its oncology trial of BOLD-100 combined with FOLFOX in the treatment of advanced gastrointestinal cancers.


Post Photo

01-13-2022

Bold Therapeutics and Hana Pharm Extend Option Agreement for BOLD-100, a First-in-Class Anti-Resistance Therapeutic

Bold Therapeutics announces an extension of the option agreement with Hana Pharm for development and commercialization rights to BOLD-100 in South Korea.


Post Photo

09-16-2021

BOLD-100 Exhibits Potent Anti-Tumor Activity in Validated I/O In Vivo Models

Bold Therapeutics has demonstrated potent anti-tumor activity in combination with a PD-1 checkpoint inhibitor in an in vivo model of colorectal cancer.


Post Photo

07-07-2021

Bold Therapeutics Receives FDA Clearance to Add U.S. Sites for Phase 1b / 2a Trial of BOLD-100 in the Treatment of Advanced GI Cancers

Bold Therapeutics announces the addition of U.S. Sites for its phase 1b / 2a trial of BOLD-100 in the treatment of advanced GI cancers.


Post Photo

06-23-2021

Bold Therapeutics Collaborates with Dr. Stephen Barr at Western University to Study BOLD-100 In COVID-19 Variants

Bold Therapeutics is pleased to be collaborating with Dr. Stephen Barr at Western University to study BOLD-100 in the COVID-19 variants of concern.


Post Photo

06-09-2020

Bold Therapeutics Receives Additional Funding to Support Development of BOLD-100 as a Novel Antiviral

Bold Therapeutics announces it is receiving additional funding of up to CAD$965,000 from NRC IRAP to support the development of BOLD-100 as a novel antiviral.


Post Photo

05-11-2021

FDA Grants Bold Therapeutics BOLD-100 an Orphan Drug Designation (ODD) in the Treatment of Gastric Cancer

Bold Therapeutics announces that the U.S. Food & Drug Administration has granted BOLD-100 an Orphan Drug Designation in the treatment of gastric cancer.


Post Photo

04-16-2021

BOLD-100 Effective In Vitro Against COVID-19 Variants

Bold Therapeutics announces that new research completed by collaborators shows BOLD-100 consistently reduced viral concentrations in COVID-19 variants.


Post Photo

04-09-2021

BOLD-100 MoA Research to Be Presented at the AACR Annual Meeting

Dr. Van Schaeybroeck will present research supporting BOLD-100 as a potential anti-resistance therapy for BRAF-mutant colorectal cancer at AACR annual meeting.


Post Photo

01-08-2021

Bold Therapeutics Secures Funding to Prepare BOLD-100 for COVID-19 Clinical Trials

Bold Therapeutics announces that it is one of four companies selected to receive funding from the National Research Council of Canada for its COVID-19 research.


Post Photo

01-06-2021

Bold Therapeutics Collaborators at University of Vienna Published Study Detailing the Binding Partners and Mechanism of Action of BOLD-100

Bold Therapeutics collaborators at University of Vienna published a study detailing the binding partners and mechanism of action of BOLD-100.


Post Photo

12-18-2020

Bold Therapeutics COVID-19 Program Chosen by National Research Council of Canada for Development Support

Bold Therapeutics BOLD-100 program was one of only four COVID-19 therapeutics programs selected by the National Research Council for development support.


Post Photo

10-09-2020

Bold Therapeutics Successfully Initiates Clinical Trial of First-in-Class Anti-Cancer Agent BOLD-100

Bold Therapeutics announced that the first patient for the company’s Phase 1b clinical trial has been enrolled at the Cross Cancer Institute.


Post Photo

09-17-2020

BOLD-100 Shows Inhibition of DNA Repair Pathways in Breast Cancer

Georgetown University has recently published a new manuscript showing that Bold Therapeutics’ BOLD-100 has anti-cancer potential in breast cancer.


Post Photo

08-17-2020

BOLD-100 Significantly Outperforms Remdesivir Head-to-Head in SARS-CoV-2 (COVID-19) Model

Bold Therapeutics recently generated additional data supporting rapid clinical development of BOLD-100 as a novel antiviral.


Post Photo

07-15-2020

BOLD-100 Demonstrates Nanomolar Range Inhibition of Live COVID-19 In Vitro

Bold Therapeutics has in vitro data showing that its lead clinical-stage therapeutic, BOLD-100, successfully inhibits live SARS-CoV-2 (COVID-19).


Post Photo

06-11-2020

Bold Therapeutics Expands COVID-19 Consortium

Bold Therapeutics is excited to expand its COVID-19 consortium to include four additional collaborators from prominent institutions in Canada and the U.K.